Bioconjugation Toolbox: Designing, Selecting, and Developing Bioconjugates for Clinical Success

Discover our latest whitepaper on bioconjugation and our expertise in finding design solutions for ADCs.

The clinical success of ADCs relies on their ability to demonstrate a sufficiently wide therapeutic index. Dose limiting toxicities are commonly observed in the clinic, emphasizing the need for careful initial design and lead selection to ensure efficacy and minimize undesired toxic side effects.

We have experience designing, producing, and evaluating a wide variety of bioconjugates. This includes peptide-drug conjugates, engineered antibody fragments conjugates, traditional ADCs, and nanoparticle conjugates, all of which are functionalized with various payloads to reflect the diversity of therapeutic applications of these types of biomolecules.

Exposure to this wide range of conjugates has led us to develop a bioconjugation toolbox to rapidly produce bioconjugate candidates with different linkers and conjugation chemistries. This allows us to explore various designs to choose from for the lead candidate.

This depth of expertise means we can optimize the therapeutic profile of ADC candidates to find the best-suited conjugation approach and linker.

Access a copy of our whitepaper today to learn more about Abzena’s expertise in finding design solutions for ADCs with our Bioconjugation Toolbox.